Bartholin gland carcinoma

Obstet Gynecol. 1986 Jun;67(6):794-801. doi: 10.1097/00006250-198606000-00009.


Bartholin gland tumors are rare and management recommendations have been based on limited information. This report summarizes a 30-year clinical experience involving Bartholin gland carcinoma in 36 patients whose five-year survival rate was 84%. FIGO stages of the 36 tumors were stage I, nine; stage II, 15; stage III, ten; and stage IV, two. Cell types were: squamous, 27 (three nonkeratinizing with areas of a transitional component); adenomatous, six; adenoid cystic, two; and adenosquamous, one. Fourteen of 30 (47%) patients with lymph node dissections had nodal metastases and 11 remain disease-free. Disease recurred in nine patients (six local, two distant, one local and distant) and four were treated successfully. One of 14 (7%) patients receiving radiation and six of 22 (27%) patients not receiving radiation developed local recurrences. Wide excision (often necessitating a radical hemivulvectomy), ipsilateral inguinal lymphadenectomy, and adjunctive irradiation to the vulva and regional lymph nodes produced excellent results.

MeSH terms

  • Adenocarcinoma* / diagnosis
  • Adenocarcinoma* / pathology
  • Adenocarcinoma* / therapy
  • Adult
  • Aged
  • Bartholin's Glands*
  • Carcinoma, Adenoid Cystic* / diagnosis
  • Carcinoma, Adenoid Cystic* / pathology
  • Carcinoma, Adenoid Cystic* / therapy
  • Carcinoma, Squamous Cell* / diagnosis
  • Carcinoma, Squamous Cell* / pathology
  • Carcinoma, Squamous Cell* / therapy
  • Carcinoma, Transitional Cell / diagnosis
  • Combined Modality Therapy
  • Diagnosis, Differential
  • Female
  • Humans
  • Lymphatic Metastasis
  • Middle Aged
  • Neoplasm Metastasis
  • Neoplasm Recurrence, Local
  • Vulva / surgery
  • Vulvar Neoplasms* / diagnosis
  • Vulvar Neoplasms* / pathology
  • Vulvar Neoplasms* / therapy